Interview with Marcin Hanczaruk, General Manager, Ferring Pharmaceuticals Poland
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
Address: ul. Bonifraterska 17
00-203 Warszawa
Poland
Tel: +48 22 246 0680
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ more than 3700 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, Israel and California, USA.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
For fifty years, we have been at the forefront of innovation in the field of naturally occurring human peptides. We have developed treatments in areas that span the human life cycle, including: reproductive health, endocrinology, gastroenterology and urology:
Ferring’s infertility treatments give infertile couples the chance to have babies
In obstetrics, Ferring helps premature children to be born healthy and without handicaps
With treatments in endocrinology, Ferring gives children the chance to overcome growth deficiencies
Ferring’s inflammatory bowel disease (IBD) treatments enable young adults with IBD to live a normal life
In urology, Ferring’s treatment for nocturia and bedwetting helps adults and children to an undisturbed night’s sleep
Ferring’s testosterone replacement treatment improves the key symptoms of low testosterone, reduces fat and improves muscle strength and mood
Ferring’s hormonal therapy for prostate cancer offers a new treatment option to men with an advanced hormone-dependent cancer
Ferring’s strength is our extensive knowledge of peptides and the role they play in the human body.
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
Some of the biggest stories coming out of the Central and Eastern European (CEE) region’s pharma industry, including the European Bank’s EUR 25 million investment in Pelion Group; the amendments…
With a geostrategic location and easy access to both Western Europe and the rest of the emerging Central and Eastern Europe (CEE) region, Poland represents the sixth largest pharma market…
Poland’s largest pharmaceutical company and leading generics manufacturer, Polpharma, is looking to expand its presence outside of the country’s borders. With a recent acquisition bid for former Sanofi European generics…
Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Polpharma’s bid for Zentiva, Richter’s acquisition of OC Distributors and MDD approval…
Some of the top stories emanating from Poland’s pharma industry, including Polish biotech Ryvu Therapeutics’ exclusive deal with Exelixis, the partnership between Polpharma and startup Pikralida on a promising epilepsy…
Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Poland’s most promising biotech start-ups, an interview with Zentiva CEO Nick Haggar,…
Every year, Polish news magazine Wprost publishes its ranking of the top 200 Polish companies across all industries. Here, we profile the top five pharma-related companies featured in the 2019 rankings.…
Reinier Schlatmann, Philips CEO in Central and Eastern Europe, talks about the strategic significance of Poland for the company and how the implementation of Philips’ strategy and its focus on…
Ewa Sek, general manager at ResMed Poland, explains the crucial role of ResMed in raising awareness on sleep apnea, COPD and other respiratory-related conditions in Poland and highlights the important…
Jan Kruk of Polish pharmaceutical logistics and distribution specialist, Cefarm, discusses the organization’s secrets of success, as well as the broader logistics and distribution landscape in Poland. As the president…
Arjo, formerly Arjo Huntleigh, has undergone a rebrand and established its first formal office in Poland in 2017. Konrad Pianko, president of the CEE region which includes over 22 countries,…
Dariusz Adamusiński, general manager of A&D Pharma’s Polish operations has a busy year ahead. A new warehouse in Poland, partnerships across the pharmaceutical spectrum coupled with new regulations are all…
See our Cookie Privacy Policy Here